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Abstract We evaluated, by an improved susceptibility testing
method, the prevalence and significance of low-level glycopep-
tide resistance in methicillin-resistant Staphylococcus aureus
(MRSA) isolates, which belonged to a previously described,
retrospective cohort of patients treated for orthopedic device-
related infections (ODRI) at the Geneva University Hospital
between 2000 and 2008. Fifty-seven individual or multiple
isolates were retrieved from 41 ODRI patients for glycopeptide
susceptibility and clonality studies, including 20 patients with
prosthetic joint (PJ) and 21 with osteosynthesis (OS) MRSA
infections. Low-level glycopeptide resistance was detected by
elevated teicoplanin or/and vancomycin minimum inhibitory
concentrations (MICs ≥4 mg/L), as determined by a previously
validated combination of macrodilution and agar dilution
assays of improved sensitivity. MRSA isolates with elevated
teicoplaninMICs were detected in 20/41 (49 %) ODRI patients
at the onset or during the course of glycopeptide therapy,
namely, in 10 of 20 patients with PJ and 10 of 21 patients with
OS infections. Only one isolate developed a concomitant in-
crease in vancomycin MIC during therapy. 13/20 (65 %)
glycopeptide-intermediate S. aureus (GISA)-infected patients,
including 7/10 (70 %) with PJ and 6/10 (60 %) with OS,
experienced treatment failure. In contrast, therapy failed in only
5/21 (24 %) ODRI patients with non-GISA isolates (p00.012),
including 2/10 (20 %) with PJ and 3/11 (27 %) with OS
infections. The emergence of low-level teicoplanin resistance
could not be explained by teicoplanin administration, since
only four patients received teicoplanin. The evaluation of
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low-level teicoplanin resistance may improve the detection of
GISA isolates. Further studies are warranted to evaluate the
impact of low-level teicoplanin resistance on the outcome of
glycopeptide therapy.
Introduction
Factors reported to increase the risk of glycopeptide treatment
failure against invasive methicillin-resistant Staphylococcus
aureus (MRSA) infections are: (1) the difficulty to reach
adequate tissue levels at the true sites of MRSA infections,
(2) the moderate bactericidal activity of glycopeptides, and (3)
the emergence of glycopeptide resistance [1–8].
Phenotypic detection of vancomycin-intermediate S. aure-
us (VISA) isolates, which are defined by vancomycin mini-
mum inhibitory concentration (MIC) breakpoints of ≥4 mg/L
and <16 mg/L, and the absence of any vancomycin or teico-
planin resistance determinants (vanA, vanB, or vanC) found in
vancomycin-resistant Enterococcus faecalis or high-level
vancomycin-resistant (vancomycin MIC: 16 mg/L) S. aureus
isolates (VRSA) [5–12] is frequently problematic [1, 2, 4–8].
Since VISA isolates are generally cross-resistant to teicopla-
nin [4, 13], they are also designated glycopeptide-intermediate
S. aureus (GISA). In contrast to vancomycin, teicoplanin
susceptibility breakpoints in S. aureus vary from 2 mg/L by
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST) [14] to 8 mg/L by the Clinical and Labo-
ratory Standards Institute (CLSI) [15].
Detection of the GISA phenotype is particularly difficult for
isolates displaying heterogeneous resistance to either or both
glycopeptide(s) (hGISA), in which only a subset of the micro-
bial population can express glycopeptide resistance [7, 9,
14–18], and which are likely precursors of GISA isolates under
the selective pressure of glycopeptides [6, 19]. The unsuccess-
ful detection of hGISA isolates by standard microbiological
methods has triggered the development of alternative assays,
such as the modified population analysis profile (PAP) area
under the curve (AUC), the Etest macromethod, and the gly-
copeptide resistance determination (GRD) test [6, 7, 20–22].
The predictive value of vancomycin and teicoplanin sus-
ceptibility breakpoints on the outcome of glycopeptide ther-
apy is still debated, despite their recent adjustment by the
CLSI and EUCAST [8, 16]. While higher rates of vanco-
mycin treatment failures were frequently reported in bacter-
emic patients infected with MRSA isolates for which
vancomycin MICs were 2 mg/L, compared to those with
lower vancomycin MICs (<2 mg/L) [1, 2, 8, 16, 23–26], as
confirmed by a recent meta-analysis [27], these data might
be explained, at least in part, by the low sensitivity of some
MIC testing methods, such as the broth microdilution and
agar dilution assays, which lead to a significant underdetec-
tion of some GISA or hGISA isolates [28–30].
While numerous studies evaluated the impact of glyco-
peptide MICs and low-level resistance on the outcome of
glycopeptide therapy in MRSA bacteremic patients [5–8,
24–26, 31], a single report linked the presence of GISA/
hGISA isolates with a negative outcome of vancomycin
therapy for MRSA-infected, orthopedic patients [32].
We recently reported a high prevalence of GISA isolates
in patients with persistent or recurrent MRSA bacteremia
[33], in which low-level glycopeptide resistance was
detected by elevated teicoplanin or/and vancomycin MICs
(≥4 mg/L), as determined by a previously validated combi-
nation of macrodilution and agar dilution assays, allowing
more sensitive detection of slow-growing, glycopeptide-“re-
sistant” subpopulations [30]. Using this improved suscepti-
bility testing method, we now present data on the prevalence
and potential significance of low-level glycopeptide resis-
tance in MRSA isolates from patients treated for orthopedic
device-related infections (ODRI) at the Geneva University
Hospital [34].
Materials and methods
Clinical and microbiological data collection
Fifty-seven MRSA isolates from 41 patients with MRSA
ODRI, who were treated at the Geneva University Hospital
between 2000 and 2008, were routinely stored in skimmed
milk/glycerol at −80 °C [34]. These ODRI patients belonged
to a retrospective cohort study, and their major clinical char-
acteristics and risk factors for treatment failure have been
previously described in detail [34]. MRSA isolates were es-
sentially intra-operative specimens and aspirated synovial flu-
id [34]. In five patients, blood isolates that were clonally
related to intra-operative isolates were also analyzed.
Twenty of the 41 ODRI patients had prosthetic joint (PJ)
and 21 osteosynthesis (OS) MRSA infection [34]. MRSA
infections were considered persistent if the patient’s clinical
status required further surgery 5 days after the initiation of
antimicrobial therapy, with isolation of the same MRSA
isolate by intra-operative specimen [34]. Recurrence was
defined as resurgence of the infection with a clonally related
MRSA isolate after the end of antimicrobial therapy [34].
Determination of glycopeptide MICs
Vancomycin and teicoplanin MICs were determined by a
slightly modified, previously described tube macrodilution
assay, using cation-adjusted Mueller–Hinton broth and stan-
dardized inocula of 106 colony-forming units (CFU)/mL [30].
MIC endpoints were read after 48 h incubation at 37 °C, to
improve the detection of slow-growing, glycopeptide-“resis-
tant” subpopulations [30]. This procedure was combined with
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a modified agar MIC testing method, which was used for
confirmatory testing of glycopeptide MICs recorded by mac-
rodilution, as previously described [30, 33]. In this modified
agar MIC testing method, residual viable counts of each
antibiotic-containing agar plate inoculated with ca. 106 CFU
were scored after 48 h incubation at 37 °C in a semi-
quantitative manner as confluent, semi-confluent, or
≤103 CFU, as previously described [30]. Glycopeptide MIC
was defined as the lowest antibiotic concentration leading to a
≥99.9% reduction in viable counts (≤103 CFU) on brain–heart
infusion agar from the uniformly applied inoculum of
106 CFU, as previously described [30].
To be scored as GISA, all MRSA isolates had to display
elevated teicoplanin or/and vancomycin MICs (≥4 mg/L) by
both modified macrodilution and agar testing assays [30, 33].
Molecular typing
The clonality of consecutive MRSA isolates from patients
with persistent or recurrent ODRI was assessed by a
variable-number tandem repeat (VNTR) genotyping method
[35], as previously described [34]. Strain pairs with >85 %
similarity in the dendrogram were considered to be clonally
related (Bioanalyzer Experiments Clustering Software) [35].
Statistical analyses
Microbiological, demographic, and clinical characteristics
of GISA- and non-GISA-infected ODRI patients were com-
pared by the Fisher’s exact test for categorical variables or
the Mann–Whitney test for continuous variables (http://vas-
sarstats.net/). Relationships were considered to be signifi-
cant when the two-sided p-value was ≤0.05.
Results
Prevalence of GISA in ODRI patients
MRSA isolates showing elevated teicoplaninMICs (≥4mg/L)
were detected in 20 (49 %) of the 41 ODRI patients, including
10 of 20 (50 %) PJ-infected and 10 of 21 (48 %) OS-infected
patients. In contrast, none of the 41 ODRI pretherapy isolates
displayed elevated vancomycin MICs (≥4 mg/L).
For two patients, teicoplanin MICs were 2 mg/L in pre-
therapy isolates and increased to 4 mg/L in subsequent
isolates. For the remaining 18 patients, teicoplanin MICs
were already elevated in pretherapy isolates and remained
constant in subsequent isolates, except for two patients in
whom teicoplanin MICs increased from 4 to 8 mg/L in
consecutive isolates. In a single patient with low-level
teicoplanin-resistant isolates, vancomycin MICs increased
from 2 to 4 mg/L from baseline to subsequent isolates.
Clonality of GISA isolates in ODRI patients
All MRSA isolates with elevated teicoplanin MICs
belonged to the hospital-acquired South German MRSA
clone ST228 (SCCmec type 1 and agr type 2), which
became predominant in our institution after 1998 [36]. This
MRSA clone was previously reported to have infected 35 of
the 41 ODRI patients (85 %) by spa and VNTR typing
methods [34]. All available sequential isolates from patients
with persistent or recurrent ODRI were clonally related (data
not shown). In contrast, none of the six residual isolates
belonging to other clonotypes (ST1, ST5, ST8, ST80,
ST239), including other SSCmec (III, IV, V) and agr (1, 3)
types [34], exhibited low-level glycopeptide resistance. The
prevalence of isolates displaying low-level glycopeptide
resistance was significantly higher in the ST228 clonotype
compared to other clonotypes (p00.021; Table 1).
Prevalence of GISA isolates and treatment outcomes
in different subgroups of ODRI patients
Thirteen of 20 GISA-infected ODRI patients (65 %) expe-
rienced MRSA-linked treatment failure compared to 5/21
(24 %) patients infected with non-GISA isolates (p00.012)
(Table 1). Treatment failure was significantly (p00.032)
higher in GISA-infected patients with persistent ODRI epi-
sodes compared to non-GISA isolates. There were also non-
significant trends toward higher rates of recurrent ODRI
episodes or multiple treatment failures in GISA-infected
compared to non-GISA-infected patients.
Higher failure rates were observed in both subgroups of
GISA-associated ODRI patients, namely, in 7/10 (70 %) PJ
and 6/10 (60 %) OS patients, compared to 2/10 (20 %) PJ
(p00.070) and 3/11 (27 %) OS patients with non-GISA
infections (p00.198; Table 1). Higher treatment failure rates
were recorded in GISA- compared to non-GISA-infected
ODRI patients with implant retention, as well as in patients
with implant removal (Table 1), but these differences did not
reach statistical significance due to the small sample sizes.
In brief, there was a consistent trend toward higher treat-
ment failure rates in all subgroups of GISA- compared to
non-GISA-infected ODRI patients.
Comparison of GISA- and non-GISA-infected patients
The major demographic and clinical characteristics of ODRI-
treated patients are presented in Table 2. Noteworthy, GISA-
infected patients were significantly younger (p00.037) than
non-GISA-infected patients. While underlying conditions and
rates of surgical debridement were similar in GISA- and non-
GISA-infected patients, there was a trend for longer duration
of hospital stay, which reached significance for the cumulated
duration of hospital stay (p00.036) in GISA- versus non-
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GISA-infected patients. While the rates of bacteremic episodes
concomitant to ODRI were not significantly different in GISA-
and non-GISA-infected patients, there was a non-significant
trend (p00.180) for a higher overall mortality in GISA-
infected (40 %; n08) compared to non-GISA-infected (19 %;
n04) patients. Most of those deaths were unrelated to MRSA-
linked ODRI or bacteremia. Only two GISA-infected patients
died from MRSA-linked ODRI or bacteremia, but death
occurred only 77 and 185 days, respectively, after ODRI onset.
Treatment modalities for GISA- and non-GISA-infected
patients
The potential impact of therapeutic regimens on the treat-
ment outcomes of GISA- compared to non-GISA-infected
ODRI patients was evaluated. Besides one patient who was
treated with trimethoprim–sulfamethoxazole, all other
patients initially received intravenous regimens of vanco-
mycin, either in monotherapy (n017) or combined with
other agents (n023). Altogether, the administration of addi-
tional antibiotic regimens to ODRI patients after initial
intravenous therapy led to a total of eight different antimi-
crobial regimens (Table 3). This great diversity and the
small sample size in each group precluded any detailed
comparison of the impact of each antimicrobial regimen
on GISA- compared to non-GISA-infected ODRI patients.
There was a trend for higher failure rates recorded in
GISA-infected patients (78 %) initially treated with vanco-
mycin monotherapy (n09), with or without additional anti-
microbial regimens, compared to the rate (38 %) in non-
GISA-infected patients (n08), which did not reach signifi-
cance (p00.153). In contrast, there were no significant dif-
ferences in the daily doses and durations of antimicrobial
regimens (data not shown) administered to GISA- versus
non-GISA-infected patients.
Several regimens of combined therapy involving vancomy-
cin associated with either rifampin, trimethoprim–sulfamethox-
azole, or fusidic acid were administered to 23 ODRI patients
(Table 3). The impact of each therapeutic regimen on the
outcome of GISA- versus non-GISA-infected ODRI patients
could not be analyzed in detail due to low sample sizes.
Interestingly, teicoplanin administration was shown to
play no significant role in the presence of GISA isolates in
ODRI patients. While only four ODRI patients received
teicoplanin as subsequent antimicrobial therapy (Table 3),
none of these patients were infected with GISA isolates.
Discussion
Despite a continuously increasing number of clinical and
microbiological reports, as summarized in [6, 7, 27], the
Table 1 Prevalence of
glycopeptide-intermediate
Staphylococcus aureus (GISA)
isolates and treatment outcomes
in different subgroups of
orthopedic device-related
infection (ODRI) patients
aSignificance of differences in
the characteristics of GISA-
versus non-GISA-infected ODRI
patients
*p<0.05
Characteristics No. of ODRI patients with indicated
type of isolate
GISA
(n020)
Non-GISA
(n021)
p- valuea
Microbiological characteristics
No. (%) of isolates belonging to the ST228 clonotype 20 (100) 15 (71) 0.021*
No. (%) of ODRI patients with MRSA-linked treatment failures 13 (65) 5 (24) 0.012*
No. (%) of patients with persistent ODRI episodes 8 (40) 2 (10) 0.032*
No. (%) of patients with recurrent ODRI episodes 5 (25) 3 (14) 0.454
No. (%) of patients with multiple treatment failures 7 (35) 3 (14) 0.159
No. (%) of PJ patients 10 (50) 10 (50) 1.000
No. (%) of PJ patients with MRSA-linked treatment failures 7 (70) 2 (20) 0.070
No. (%) of PJ patients with removed implants 4 (57) 3 (43) 1.000
No. (%) of treatment failures 3 (75) 0 (<25) 0.142
No. (%) of PJ patients with implant retention 6 (46) 7 (54) 1.000
No. (%) of treatment failures 4 (75) 2 (29) 0.286
No. (%) of OS patients 10 (48) 11 (52) 1.000
No. (%) of OS patients with MRSA-linked treatment failures 6 (60) 3 (27) 0.198
No. (%) of OS patients without debridement 2 (10) 2 (10) 1.000
No. (%) of OS patients with removed implants 3 (43) 4 (57) 1.000
No. (%) of treatment failures 1 (25) 0 (<25) 0.429
No. (%) of OS patients with implant retention 5 (50) 5 (50) 1.000
No. (%) of treatment failures 3 (60) 1 (20) 0.524
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impact of low-level glycopeptide resistance on the outcome
of GISA infections is still debated. This unclear situation
mostly results from technical issues in characterizing the
low-level glycopeptide resistance phenotype in MRSA
isolates, which is frequently heterogeneous and, thus,
escapes detection by standard MIC assays. Furthermore,
there is no molecular assay for detecting low-level
glycopeptide resistance, whose molecular basis is likely
multifactorial and may even display some strain-specific
variability [37]. While a recent meta-analysis supports the
concept that slightly elevated vancomycin MICs, scored
at the higher end of the susceptibility range by micro-
dilution or Etest, were associated with worse outcomes of
glycopeptide therapy in MRSA bloodstream infections,
Table 2 Demographic and
clinical characteristics of
patients with GISA and
non-GISA ODRI episodes
aSignificance of differences in
the characteristics of GISA-
versus non-GISA-infected ODRI
patients
*p<0.05
Characteristics No. of ODRI patients with indicated type
of isolate
GISA
(n020)
Non-GISA
(n021)
p- valuea
Demographic characteristics
Age [median years (range)] 62 (35–78) 78 (22–82) 0.037*
Female gender 12 (60) 11 (52) 0.756
Underlying conditions
At least one underlying illness 12 (60) 15 (71) 0.520
Diabetes mellitus 1 (5) 4 (19) 0.343
Charlson comorbidity index (mean±SE) 1.47 (0.35) 1.38 (0.29) 0.800
No. (%) of patients with surgical debridement 18 (90) 19 (90) 1.000
Median no. (range) of surgical interventions 3 (1–10) 1 (1–5) 0.025*
Duration [median no. of days (range) of initial hospital stay] 42 (9–195) 32 (1–88) 0.234
Median no. (range) of hospitalizations 1.5 (1–7) 1 (1–2) 0.052
Duration [median no. of days (range) of cumulated hospital stay] 53.5 (23–195) 34 (1–108) 0.036*
No. (%) of patients with concomitant bacteremia 3 (15) 6 (28) 0.453
No. (%) of patients with exitus 8 (40) 4 (19) 0.180
Table 3 Treatment regimens of
patients with GISA and non-
GISA ODRI episodes
NA not applicable; LZD line-
zolid; RIF rifampin; SXT tri-
methoprim–sulfamethoxazole;
VAN vancomycin; TEC
teicoplanin
aSignificance of differences in
the treatment regimens and out-
comes of GISA- and non-GISA-
infected ODRI patients
bTwo GISA and two non-GISA-
infected patients received SXT
and three non-GISA-infected
patients received TEC
cTwo GISA and one non-GISA-
infected patients received SXT,
two GISA and eight non-GISA-
infected patients RIF + fusidic
acid, one non-GISA patient RIF
+ LZD, and one non-GISA pa-
tient received TEC
Initial antibiotic regimen No. of ODRI patients with indicated type
of isolate
GISA
(n020)
Non-GISA
(n021)
p- valuea
No. (%) of patients with VAN monotherapy 9 (45) 8 (38) 1.000
Failure rate (%) 7 (78) 3 (38) 0.153
No. (%) of patients with VAN alone 7 (35) 3 (14) 0.159
Failure rate (%) 5 (71) 1 (33) 0.500
No. (%) of patients with VAN + subsequent antibiotic therapyb 2 (10) 5 (24) 0.410
Failure rate (%) 2 (100) 2 (40) 0.429
No. (%) of patients with SXT monotherapy 1 (5) 0 (<5) NA
Failure rate (%) 1 (100) 0 (NA) NA
No. (%) of patients with VAN in combination 10 (50) 13 (62) 0.538
Failure rate (%) 5 (50) 2 (15) 0.169
No. (%) of patients with combined VAN + SXT therapy 1 (5) 1 (5) NA
Failure rate (%) 1 (100) 1 (100) NA
No. (%) of patients with combined VAN + RIF therapy 9 (45) 12 (57) 0.538
Failure rate (%) 4 (44) 1 (8) 0.119
No. (%) of patients with VAN + RIF + subsequent oral
antibiotic therapyc
4 (20) 10 (48) 0.100
Failure rate (%) 2 (40) 0 (<10) 0.066
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the contribution of hGISA could not be evaluated in this
context [27].
To facilitate the detection of hGISA or GISA by standard
MIC criteria, we developed a modified macrodilution MIC
assay by using higher inocula than broth microdilution MIC
and extending the incubation period to 48 h at 37 °C, which
is mandatory for detecting the slowly growing resistant
subpopulations [30]. The increased sensitivities of the mod-
ified macrodilution assay combined with a modified agar
MIC method markedly increased the detection rates of iso-
lates with slightly elevated teicoplanin and vancomycin
MICs (≥4 mg/L), by ca. 10-fold and 4-fold, respectively,
compared to broth microdilution [30]. Most recently, the
modified macrodilution MIC assay allowed detecting a
higher prevalence of MRSA isolates with slightly elevated
vancomycin or teicoplanin MICs in patients with persistent
or recurrent episodes of MRSA bacteremia compared to
those with single episodes [33]. Collectively, these data
strongly suggest that a significant proportion of MRSA
bloodstream isolates scored with slightly elevated vancomy-
cin MICs (2 mg/L) by microdilution in previous studies [24,
27, 38] could have been undetected VISA or hVISA.
Since our previous contributions indicated that >95 % of
isolates with elevated vancomycin MICs displayed cross-
resistance to teicoplanin, elevated teicoplanin MIC was con-
sidered to be a reliable marker of the GISA phenotype,
which could facilitate the screening of isolates with low-
level vancomycin resistance [13, 30]. Indeed, in our recent
study of patients with persistent or recurrent episodes of
MRSA bacteremia, 63 % of isolates displaying low-level
resistance to teicoplanin were concomitantly resistant to
vancomycin [33].
In contrast to patients with MRSA bloodstream infec-
tions, vancomycin cross-resistance was a rare event in
teicoplanin-resistant isolates from ODRI patients. Indeed,
only one patient among all of the teicoplanin-resistant iso-
lates detected in 20 patients displayed concomitant resis-
tance to vancomycin. Noteworthy, teicoplanin-resistant
isolates were already present in 90 % of GISA-infected
ODRI patients at the onset of antimicrobial therapy, while
the emergence of low-level teicoplanin resistance during
therapy occurred in only 10 % of the patients. Remarkably,
the administration of teicoplanin therapy was not associated
with the emergence of low-level teicoplanin-resistant iso-
lates, since none of the four teicoplanin-treated patients were
infected with resistant isolates.
A most intriguing finding of this study was that ODRI
patients infected with MRSA isolates displaying low-level
teicoplanin resistance but still showing in vitro susceptibility
to vancomycin seemed to respond poorly to antimicrobial
regimens involving vancomycin compared to non-GISA-
infected patients These observations lead us to speculate
that in vivo conditions prevailing in ODRI patients might
significantly alter the metabolic parameters of MRSA in
such a way that teicoplanin resistance mechanisms may
compromise MRSA susceptibility to vancomycin therapy.
Previous studies performed in an animal model of chronic,
implant-associated MRSA infection indicated a drastic loss
of susceptibility to antibiotic killing in bacteria directly
removed from infected foci [39–42]. Other important
parameters that may contribute to bacterial survival in
MRSA chronic infections are intracellular persistence [43],
which may be further promoted by teicoplanin resistance
determinants [44], and bacterial adherence, leading to biofilm
formation and colonization of artificial surfaces [41, 45, 46].
Recent molecular studies indicated that the emergence of
vancomycin and teicoplanin endogenous resistance is likely
a stepwise process involving several mutations in key reg-
ulatory genes [6, 13, 37]. While the molecular differences
between isolates displaying combined low-level resistance
to both teicoplanin and vancomycin versus those resistant to
teicoplanin alone have not been elucidated, molecular stud-
ies performed in our laboratory suggest that resistance to
teicoplanin alone might represent an early step of low-level
glycopeptide resistance, which may eventually lead to van-
comycin resistance via additional mutations [37]. In this
context, the exclusive presence of GISA isolates in a single
MRSA clonotype, namely, the South German clone ST228
or relatives, which became predominant in ODRI MRSA
infections reported in our institution from 2000 to 2008 [34,
36], as opposed to its absence in other clonotypes, is re-
markable. It is possible that the ST228 clonal family, which
is characterized by SCCmec type 1 and agr type 2, may
contain some phenotypically silent mutations predisposing
to the emergence of glycopeptide resistance.
The complexity of the clinical data, in particular, the high
diversity of surgical procedures and antimicrobial regimens
administered to ODRI patients, did not allow a detailed risk
factor analysis of GISA- compared to non-GISA-infected
ODRI patients. Our previous report analyzing the overall
impact of antimicrobial therapy on the outcome of all
MRSA-infected ODRI patients revealed the significant ben-
efit on patient outcome of a combined rifampin–fusidic acid
regimen administered after initial rifampin–vancomycin
therapy [34]. Controlled trials involving larger groups of
MRSA ODRI patients are needed in order to evaluate the
efficacy of the rifampin–fusidic acid combination over other
regimens, against GISA- as well as non-GISA-infected
patients.
This study has some limitations. This was a single-center,
retrospective cohort study, which required extended follow-
up periods for the clinical and microbiological evaluations
of ODRI patients. Failure of glycopeptide therapy in MRSA
ODRI patients is clearly multifactorial, as found in several
studies, being influenced by several demographic and clin-
ical risk factors in addition to the emergence of reduced
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susceptibility to glycopeptides. The difficulty in recruiting
adequate numbers of GISA- and non-GISA-infected ODRI
patients for comparative studies leads to small sample sizes
that prevent detailed analysis of risk factors. In some parts of
our study, both OS and PJ patients with persistent and
recurrent GISA ODRI episodes had to be analyzed collec-
tively in view of the small numbers.
In conclusion, the development of simple, more sensitive
MIC assays for detecting GISA isolates should prompt the
development of a multicenter, prospective study for evalu-
ating the impact of the GISA phenotype and clinical risk
factors on the outcome of glycopeptide therapy in MRSA
ODRI patients. In particular, multicenter controlled studies
are needed so as to define the most adequate antibiotic
regimen(s) for such infections.
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